Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Quinine
Drug ID BADD_D01895
Description An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
Indications and Usage For the treatment of malaria and leg cramps
Marketing Status approved
ATC Code P01BC01
DrugBank ID DB00468
KEGG ID D08460; D08461
MeSH ID D011803
PubChem ID 3034034
TTD Drug ID D03DDR
NDC Product Code 65162-811
UNII A7V27PHC7A
Synonyms Quinine | Quinimax | Quinine Bisulfate | Bisulfate, Quinine | Quinine Hydrochloride | Hydrochloride, Quinine | Myoquin | Quinamm | Quinbisan | Legatrim | Quinine Lafran | Quinine Sulfate | Sulfate, Quinine | Quinine Sulphate | Sulphate, Quinine | Quinine-Odan | Quinoctal | Surquina | Biquinate | Strema | Quindan | Quinbisul | Quinson | Quinsul
Chemical Information
Molecular Formula C20H24N2O2
CAS Registry Number 72402-53-0
SMILES COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Papule23.03.03.038--Not Available
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Photophobia17.17.02.006; 06.01.01.0040.000734%
Photosensitivity reaction23.03.09.003--
Plasmodium falciparum infection01.03.02.012; 11.06.04.003--Not Available
Pre-existing condition improved08.01.03.0430.002495%Not Available
Pruritus23.03.12.001--
Pulmonary oedema22.01.03.003; 02.05.02.003--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rash maculo-papular23.03.13.004--
Rash scarlatiniform23.03.13.006--Not Available
Renal failure20.01.03.005--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Retinal artery occlusion06.10.01.005; 24.01.07.0030.001835%Not Available
Retinal degeneration06.09.03.0020.002202%Not Available
Retinal depigmentation06.09.03.0040.001101%Not Available
Retinal disorder06.08.03.0050.001101%Not Available
Retinal oedema06.04.06.007; 24.03.07.0060.001101%Not Available
Retinal vascular disorder24.03.07.002; 06.10.01.0020.001101%
Retinopathy24.03.07.003; 06.10.02.0010.001468%
Rhabdomyolysis15.05.05.0020.002202%
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.0060.001101%
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.0050.001101%
Sudden visual loss06.02.10.011; 17.17.01.014--Not Available
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene